OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
OPKO Health (NASDAQ: OPK) will report its third-quarter 2026 operating and financial results on Wednesday, November 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
OPKO Health (NASDAQ: OPK) will report its third-quarter 2026 operating and financial results on Wednesday, November 4, 2026.
Senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update and discuss results and financial guidance.
Key Figures
- Results reporting date
- November 4, 2026
- Third-quarter 2026 operating and financial results
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 on Wednesday, November 4, 2026. OPKO’s senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.
CONFERENCE CALL & WEBCAST INFORMATION
OPKO encourages participants to pre-register for the conference call using this link. Participants who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed through OPKO’s Investor Relations here.
A telephone replay will be available until November 11, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 3222736. A webcast replay will be available beginning approximately one hour after the completion of the live conference call through OPKO’s Investor Relations here.
About OPKO Health
OPKO Health, Inc. is a multinational biopharmaceutical company focused on developing and delivering therapeutics for serious diseases across global markets. The company’s research and development programs include multispecific antibody technologies, in vivo CAR-T delivered through antibody-guided lipid nanoparticles, and proprietary long-acting peptide and protein engineering capabilities. OPKO also operates specialty pharmaceutical businesses across several international markets.
For more information, visit www.opko.com.
Contacts:
Alliance Advisors IR
Vivian Cervantes, 973-873-7724
vcervantes@allianceadvisors.com
